These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18820805)

  • 61. Banting lecture 1986. Does a common mechanism induce the diverse complications of diabetes?
    Winegrad AI
    Diabetes; 1987 Mar; 36(3):396-406. PubMed ID: 3026877
    [No Abstract]   [Full Text] [Related]  

  • 62. [Advanced glycation end products and hyperglycaemia].
    Omsland TK; Bangstad HJ; Berg TJ; Kolset SO
    Tidsskr Nor Laegeforen; 2006 Jan; 126(2):155-8. PubMed ID: 16415936
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of pancreatic transplantation on diabetic complications.
    Munda R; First MR; Kranias G; Alexander JW
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2865-6. PubMed ID: 2650389
    [No Abstract]   [Full Text] [Related]  

  • 64. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
    Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
    Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of pancreas transplantation on diabetic secondary complications and quality of life.
    Landgraf R
    Diabetologia; 1996 Dec; 39(12):1415-24. PubMed ID: 8960821
    [No Abstract]   [Full Text] [Related]  

  • 66. [Blood sugar should be normalized in diabetic patients].
    Pirart J
    Union Med Can; 1985 Oct; 114(10):813-4, 817-20. PubMed ID: 4082350
    [No Abstract]   [Full Text] [Related]  

  • 67. The Role of Oxidative Stress in Diabetic Neuropathy: Generation of Free Radical Species in the Glycation Reaction and Gene Polymorphisms Encoding Antioxidant Enzymes to Genetic Susceptibility to Diabetic Neuropathy in Population of Type I Diabetic Patients.
    Babizhayev MA; Strokov IA; Nosikov VV; Savel'yeva EL; Sitnikov VF; Yegorov YE; Lankin VZ
    Cell Biochem Biophys; 2015 Apr; 71(3):1425-43. PubMed ID: 25427889
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Complications of diabetes mellitus].
    Goto Y
    Nihon Naika Gakkai Zasshi; 1985 Dec; 74(12):1635-51. PubMed ID: 3831189
    [No Abstract]   [Full Text] [Related]  

  • 69. [Complications and associated diseases of diabetes mellitus. 3. Correlations between associated diseases in diabetes mellitus].
    Franke E
    Z Gesamte Inn Med; 1971 Apr; 26(7):237-40. PubMed ID: 5571724
    [No Abstract]   [Full Text] [Related]  

  • 70. The AGE-receptor in the pathogenesis of diabetic complications.
    Vlassara H
    Diabetes Metab Res Rev; 2001; 17(6):436-43. PubMed ID: 11757079
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Metabolic syndrome and microangiopathy.
    Szalat A; Raz I
    Isr Med Assoc J; 2006 Jun; 8(6):424-5. PubMed ID: 16833174
    [No Abstract]   [Full Text] [Related]  

  • 72. Inhibitory effect of phenolic compounds and plant extracts on the formation of advance glycation end products: A comprehensive review.
    Khan M; Liu H; Wang J; Sun B
    Food Res Int; 2020 Apr; 130():108933. PubMed ID: 32156381
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Risk factors for diabetic complications: Oxidative stress].
    Osawa T
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():53-9. PubMed ID: 12430207
    [No Abstract]   [Full Text] [Related]  

  • 74. [Participation of toxic AGEs (TAGE) in a variety of diseases].
    Takeuchi M
    Nihon Yakurigaku Zasshi; 2012 May; 139(5):193-7. PubMed ID: 22687870
    [No Abstract]   [Full Text] [Related]  

  • 75. [Advanced glycation end products (AGEs) and renal failure].
    Kurowski R; Manitius J
    Przegl Lek; 2006; 63(4):203-8. PubMed ID: 17080743
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.
    Schalkwijk CG; Miyata T
    Amino Acids; 2012 Apr; 42(4):1193-204. PubMed ID: 20960212
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A quick, simple method for detecting circulating fluorescent advanced glycation end-products: Correlation with in vitro and in vivo non-enzymatic glycation.
    Villa M; Parravano M; Micheli A; Gaddini L; Matteucci A; Mallozzi C; Facchiano F; Malchiodi-Albedi F; Pricci F
    Metabolism; 2017 Jun; 71():64-69. PubMed ID: 28521879
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
    Yamagishi S
    Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy.
    Koschinsky T; He CJ; Mitsuhashi T; Bucala R; Liu C; Buenting C; Heitmann K; Vlassara H
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6474-9. PubMed ID: 9177242
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Calcium antagonists: current and future applications based on new evidence. Calcium antagonists and diabetes].
    Yamagishi S
    Clin Calcium; 2010 Jan; 20(1):77-82. PubMed ID: 20048437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.